Analysis of TCR2 Therapeutics Inc. (NASDAQ:TCRR): Selected Notes

The closing price of TCR2 Therapeutics Inc. (NASDAQ: TCRR) was $1.36 for the day, up 3.82% from the previous closing price of $1.31. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 500699 shares were traded. TCRR stock price reached its highest trading level at $1.3700 during the session, while it also had its lowest trading level at $1.3250.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



Our analysis of TCRR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.00 and its Current Ratio is at 5.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on January 19, 2022, Downgraded its rating to Neutral and sets its target price to $5 from $28 previously.

SVB Leerink Downgraded its Outperform to Mkt Perform on October 21, 2021, whereas the target price for the stock was revised from $18 to $8.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 13 when Cardama Alfonso Quintas sold 4,752 shares for $1.06 per share. The transaction valued at 5,042 led to the insider holds 109,459 shares of the business.

Olagunju Peter sold 1,659 shares of TCRR for $1,767 on Dec 13. The Chief Technical Officer now owns 24,092 shares after completing the transaction at $1.06 per share. On Dec 13, another insider, Menzel Garry E, who serves as the President and CEO of the company, sold 11,000 shares for $1.06 each. As a result, the insider received 11,682 and left with 138,871 shares of the company.

Stock Price History:

Over the past 52 weeks, TCRR has reached a high of $3.88, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is 1.1826, while the 200-Day Moving Average is calculated to be 2.1686.

Shares Statistics:

TCRR traded an average of 308.80K shares per day over the past three months and 303.65k shares per day over the past ten days. A total of 38.62M shares are outstanding, with a floating share count of 38.34M. Insiders hold about 1.40% of the company’s shares, while institutions hold 66.00% stake in the company. Shares short for TCRR as of Oct 13, 2022 were 1.98M with a Short Ratio of 1.17M, compared to 2.17M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.12% and a Short% of Float of 6.40%.

Earnings Estimates

The firm’s stock currently is rated by 9 analysts. On average, analysts expect EPS of -$0.83 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.93, while EPS last year was -$0.69. The consensus estimate for the next quarter is -$0.81, with high estimates of -$0.37 and low estimates of -$0.98.

Analysts are recommending an EPS of between -$2.76 and -$3.46 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is -$2.41, with 8 analysts recommending between -$1.12 and -$4.68.